In a recent study, FLT3 and/or IDH inhibitors (FLT3Is and/or IDHIs) were administered as a single agent or in combination with cytotoxic chemotherapy (CCT) or low-intensity therapy (LIT) in 91 AML patients with FLT3-ITD/IDH1 or FLT3-ITD/IDH2 double mutations. This evidence concerns the gene IDH1 and acute myeloid leukemia.